William Blair Issues Negative Estimate for ARCT Earnings

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) – Equities researchers at William Blair cut their Q1 2025 earnings estimates for Arcturus Therapeutics in a report released on Thursday, March 13th. William Blair analyst M. Minter now expects that the biotechnology company will earn ($1.39) per share for the quarter, down from their previous forecast of ($0.53). The consensus estimate for Arcturus Therapeutics’ current full-year earnings is ($2.22) per share. William Blair also issued estimates for Arcturus Therapeutics’ Q2 2025 earnings at ($1.41) EPS, Q3 2025 earnings at ($1.15) EPS, Q4 2025 earnings at ($1.36) EPS, FY2025 earnings at ($5.31) EPS, Q1 2026 earnings at ($1.39) EPS, Q2 2026 earnings at ($1.48) EPS, Q3 2026 earnings at ($1.52) EPS, Q4 2026 earnings at ($1.59) EPS, FY2026 earnings at ($5.98) EPS and FY2027 earnings at $0.41 EPS.

Several other equities research analysts have also recently weighed in on ARCT. Wells Fargo & Company dropped their price target on shares of Arcturus Therapeutics from $58.00 to $50.00 and set an “overweight” rating for the company in a research report on Friday, March 7th. Cantor Fitzgerald reissued an “overweight” rating on shares of Arcturus Therapeutics in a research report on Friday, March 7th. BTIG Research set a $48.00 price target on shares of Arcturus Therapeutics and gave the company a “buy” rating in a research report on Monday, March 10th. HC Wainwright dropped their price target on shares of Arcturus Therapeutics from $63.00 to $60.00 and set a “buy” rating for the company in a research report on Friday, March 7th. Finally, Canaccord Genuity Group dropped their price target on shares of Arcturus Therapeutics from $74.00 to $68.00 and set a “buy” rating for the company in a research report on Monday, March 10th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Arcturus Therapeutics presently has a consensus rating of “Buy” and an average target price of $59.20.

Arcturus Therapeutics Stock Performance

Shares of Arcturus Therapeutics stock opened at $14.16 on Monday. The company’s 50 day moving average price is $16.54 and its 200-day moving average price is $18.24. Arcturus Therapeutics has a 52-week low of $12.75 and a 52-week high of $45.00. The stock has a market capitalization of $384.02 million, a price-to-earnings ratio of -6.38 and a beta of 2.96.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings results on Thursday, March 6th. The biotechnology company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.78). Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. The company had revenue of $22.77 million for the quarter, compared to the consensus estimate of $44.64 million.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ARCT. Balyasny Asset Management L.P. bought a new position in Arcturus Therapeutics in the 4th quarter worth $9,312,000. Schonfeld Strategic Advisors LLC raised its holdings in Arcturus Therapeutics by 129.7% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 849,081 shares of the biotechnology company’s stock worth $14,409,000 after purchasing an additional 479,482 shares in the last quarter. J. Goldman & Co LP bought a new position in shares of Arcturus Therapeutics in the 4th quarter worth about $5,024,000. MPM Bioimpact LLC increased its stake in shares of Arcturus Therapeutics by 109.5% in the 4th quarter. MPM Bioimpact LLC now owns 459,943 shares of the biotechnology company’s stock worth $7,805,000 after acquiring an additional 240,435 shares in the last quarter. Finally, Empire Life Investments Inc. increased its stake in shares of Arcturus Therapeutics by 85.5% in the 4th quarter. Empire Life Investments Inc. now owns 279,463 shares of the biotechnology company’s stock worth $4,742,000 after acquiring an additional 128,771 shares in the last quarter. 94.54% of the stock is currently owned by institutional investors.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.